BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10376864)

  • 1. Comparison of ovarian electrocautery and oral contraceptives in the treatment of hyperandrogenism in women with polycystic ovary syndrome.
    Gjønnaess H
    Acta Obstet Gynecol Scand; 1999 Jul; 78(6):530-3. PubMed ID: 10376864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
    Mastorakos G; Koliopoulos C; Creatsas G
    Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
    Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in plasma levels of androgens and SHBG in patients with polycystic ovary syndrome (PCOs) treated with oral contraceptives containing desogestrel].
    Negri P; D'Errico G; Minisci N; Tomasi A
    Minerva Ginecol; 1988 Dec; 40(12):699-707. PubMed ID: 2977429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
    Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ
    Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome.
    Gjønnaess H
    Fertil Steril; 1998 Apr; 69(4):697-701. PubMed ID: 9548160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of insulin resistance on the outcome of laparoscopic ovarian electrocautery in infertile women with the polycystic ovary syndrome.
    Dale PO; Tanbo T; Ertzeid G; Bjercke S; Oldereid N; Fedorcsák P; Abyholm T
    Gynecol Endocrinol; 2004 Oct; 19(4):182-9. PubMed ID: 15724800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.
    Armstrong VL; Wiggam MI; Ennis CN; Sheridan B; Traub AI; Atkinson AB; Bell PM
    QJM; 2001 Jan; 94(1):31-7. PubMed ID: 11161134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
    Elter K; Imir G; Durmusoglu F
    Hum Reprod; 2002 Jul; 17(7):1729-37. PubMed ID: 12093831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
    Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
    Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.